The myth that’s been floating around: the FDA crackdown in March 2025 killed compounded peptides for good. Here’s what actually happened: they didn’t get banned. The personalized-prescription exception is still there in regulation. What shifted is where you can access them and which pharmacies learned to work through the new landscape. If you’re in a state with delivery and a pharmacy that still compounds (Hallandale, ProRx, Greenwich, some of the 503B operations), you can still run them. If you’re not in those states, options either compress or prices jump. The mechanics behind why it feels dead in some places:
- FDA clarified 503A and 503B boundaries; pharmacy networks got cautious
- Many state boards tightened their compounding oversight independently
- Supply got thinner where fewer pharmacies continued, so prices climbed
- Geographic lottery happened: still accessible in some states, blocked or cost-prohibitive in others
- The personalized-prescription carve-out is still in the rules, but enforcement is state-by-state What it means in practice: it’s not gone, it’s just fragmented now. If you’ve got access where you’re, the tool is still there. If you don’t, brand programs or other options become the play